Milliman pharmacists and healthcare experts explain what strategies state Medicaid agencies are using for predicting uptake and covering these high costs.
Multiemployer pension plans receiving special financial assistance should review the latest key changes to the withdrawal liability, among other recent guidance.
Beyond epidemiology, clinical trial criteria, and the science
This research paper examines the prevalence of rare diseases in a U.S. commercial population using claims data.
This paper introduces why self-insured employers with stop-loss coverage may still be exposed to some of the costs of gene and cell therapies, explores considerations and a potential imbalance of financial risk for the self-insured employer and stop-loss carrier when implementing a multiyear performance-based payment arrangement, and discusses potential ways to efficiently contract between the self-insured employer, stop-loss carrier, and manufacturer to better share the financial risk.
Evaluating multiyear payment arrangements? Assess retention rates for patients with rare diseases.
Insurers, policymakers, and government agencies in the United States may find it useful to have an accurate expectation for the length of enrollment by subscribers with a dependent who suffers from a pediatric rare disease and may be a candidate for a regenerative therapy with a potentially prolonged benefit.
When it comes to gene and cell therapies, there are a number of risks and benefits that payers should consider.